Citations

Mayo Clinic

Showing 10 of 108551 citations.

MR Imaging of Endometrial Cancer that Occurs After Radiation Therapy for Cervix Cancer
Lim, Nam Yeol, Ko, Seok Wan, Kim, Youn Jeong , Jeong, Yong Yeon , Kim, Bo Hyun

Journal of the Korean Radiological Society | January 25, 2016 | Volume: 56 | Issue: 5 | Pages: 491

10.3348/jkrs.2007.56.5.491 Get It

Author response: Reconstructing the in vivo dynamics of hematopoietic stem cells from telomere length distributions
Lassay, Lisa, Orlikowsky, Thorsten , Brümmendorf, Tim H., Werner, Benjamin , Beier, Fabian , Hummel, Sebastian , Balabanov, Stefan , Dingli, David , Traulsen, Arne

No container title available | January 25, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.08687.019 Get It

Chronic Subcutaneous Brain Natriuretic Peptide Therapy in Asymptomatic Systolic Heart Failure
Schirger, John A., Benike, Sherry L., Harstad, Lynn K., Slusser, Joshua P. , Hodge, David O. , Redfield, Margaret M. , Burnett, John C. , Chen, Horng H. , McKie, Paul M.

European Journal of Heart Failure | January 24, 2016 | Volume: 18 | Issue: 4 | Pages: 433-441

10.1002/ejhf.468 | PMID 26806605 Get It

Abstract Aims We have previously reported that asymptomatic systolic heart failure (HF) is characterized by an impaired renal response to volume expansion due to lack of activation of urinary cGMP which is corrected by subcutaneous (SQ) BNP. In the current study, we sought to define the cardiorenal response to intravascular volume expansion after 12 weeks of SQ BNP therapy. Methods and results We utilized a double-blinded, placebo-controlled study to compare 12 weeks of twice-daily SQ BNP 10 µg/kg (n = 22) or placebo (n = 12) in asymptomatic systolic HF. Subjects underwent two study visits: baseline and after 12 weeks of therapy. At each study visit, echocardiography, renal, and neurohumoral assessments were performed before and after intravascular volume expansion. The primary endpoint was change in urinary sodium excretion in response to volume expansion at 12 weeks, and we observed a greater increase in urinary sodium excretion [166 (77, 290) vs. 15 (−39, 72) mEq/min; P = 0.02] with SQ BNP treatment vs. placebo. Secondary endpoints included change in urine flow and glomerular filtration rate (GFR) in response to volume expansion at 12 weeks. We observed a significant increase in urine flow (P < 0.01) and trend for differential response in GFR (P = 0.08) with SQ BNP treatment vs. placebo. Conclusion Among patients with asymptomatic systolic HF, twice-daily SQ BNP therapy improved the cardiorenal response to volume expansion at 12-week follow-up. Further studies are warranted to determine if these beneficial physiological observations with chronic natriuretic peptide administration translate into a delay in the progression to symptomatic HF.
Driveline Infection Risk with Utilization of a Temporary External Anchoring Suture After Implantation of a Left Ventricular Assist Device
Fudim, Marat , Brown, Christopher L. , Djunaidi, M., Danter, Matthew , Stulak, John M., Haglund, Nicholas, Maltais, Simon, Davis, Mary Elizabeth , Harrell, Frank E.

ASAIO Journal | January 24, 2016 | Volume: 62 | Issue: 3 | Pages: 291-296

10.1097/mat.0000000000000346 | PMID 26809083 Get It

Driveline infections (DLI) are a cause of morbidity after continuous-flow left ventricular assist device (CF-LVAD) implantation. Because driveline trauma contributes to DLI, we assessed whether intraoperative placement of a temporary external anchoring suture (EAS) influenced DLI rate. We analyzed 161 consecutive patients with CF-LVAD (HMII 82; HW 79) implantation. Two groups were defined: placement of EAS (n = 85) or No EAS (n = 76). For NO EAS patients, the driveline was permanently anchored internally to the rectus fascia. Cox proportional analysis was performed to assess the effect of EAS on time to first confirmed DLI. Baseline characteristics were comparable between groups (all p = 0.3). Mean follow-up time was 0.93 years. A total of 18 (11.1%) patients developed confirmed culture positive DLI, with “first infection” rate of 0.13 events/year. Mean time to confirmed DLI was 0.69 years. Driveline infection was less likely (hazard ratio [HR] = 0.28, 0.95 confidence interval [CI] = 0.06–1.25, p = 0.056) to occur in NO EAS (2/18) then in EAS (16/18). Confirmed DLI was comparable between device types (p = 0.3). Multivariable regression adjusted for age, BMI, blood product use, device type, and diabetes showed equivocal effect of EAS (HR = 0.33, 0.95 CI = 0.07–1.54, p = 0.12). Patients with a temporary EAS may have an increased risk of confirmed DLI after device implantation.
Proposal for a Standard Format for Neurophysiology Data Recording and Exchange
Stead, Matt, Halford, Jonathan J. , Halford, Jonathan J

Journal of Clinical Neurophysiology | January 24, 2016 | Volume: 33 | Issue: 5 | Pages: 403-413

10.1097/wnp.0000000000000257 | PMID 26808620 Get It

Summary: The lack of interoperability between information networks is a significant source of cost in health care. Standardized data formats decrease health care cost, improve quality of care, and facilitate biomedical research. There is no common standard digital format for storing clinical neurophysiologic data. This review proposes a new standard file format for neurophysiology data (the bulk of which is video-electroencephalographic data), entitled the Multiscale Electrophysiology Format, version 3 (MEF3), which is designed to address many of the shortcomings of existing formats. MEF3 provides functionality that addresses many of the limitations of current formats. The proposed improvements include (1) hierarchical file structure with improved organization; (2) greater extensibility for big data applications requiring a large number of channels, signal types, and parallel processing; (3) efficient and flexible lossy or lossless data compression; (4) industry standard multilayered data encryption and time obfuscation that permits sharing of human data without the need for deidentification procedures; (5) resistance to file corruption; (6) facilitation of online and offline review and analysis; and (7) provision of full open source documentation. At this time, there is no other neurophysiology format that supports all of these features. MEF3 is currently gaining industry and academic community support. The authors propose the use of the MEF3 as a standard format for neurophysiology recording and data exchange. Collaboration between industry, professional organizations, research communities, and independent standards organizations is needed to move the project forward.
Epidemiology of Acute Respiratory Distress Syndrome Following Hematopoietic Stem Cell Transplantation*
Yadav, Hemang , Nolan, Matthew , Bohman, J. Kyle , Cartin‐Ceba, Rodrigo , Peters, Steve G. , Kor, Daryl J. , Hogan, William J. , Gajic, Ognjen , Bohman, John K

Critical Care Medicine | January 24, 2016 | Volume: 44 | Issue: 6 | Pages: 1082-1090

10.1097/ccm.0000000000001617 | PMID 26807683 Get It

Objectives: Pulmonary complications are common following hematopoietic stem cell transplantation. Numerous idiopathic post-transplantation pulmonary syndromes have been described. Patients at the severe end of this spectrum may present with hypoxemic respiratory failure and pulmonary infiltrates, meeting criteria for acute respiratory distress syndrome. The incidence and outcomes of acute respiratory distress syndrome in this setting are poorly characterized. Design: Retrospective cohort study. Setting: Mayo Clinic, Rochester, MN. Patients: Patients undergoing autologous and allogeneic hematopoietic stem cell transplantation between January 1, 2005, and December 31, 2012. Interventions: None. Measurements and Main Results: Patients were screened for acute respiratory distress syndrome development within 1 year of hematopoietic stem cell transplantation. Acute respiratory distress syndrome adjudication was performed in accordance with the 2012 Berlin criteria. In total, 133 cases of acute respiratory distress syndrome developed in 2,635 patients undergoing hematopoietic stem cell transplantation (5.0%). Acute respiratory distress syndrome developed in 75 patients (15.6%) undergoing allogeneic hematopoietic stem cell transplantation and 58 patients (2.7%) undergoing autologous hematopoietic stem cell transplantation. Median time to acute respiratory distress syndrome development was 55.4 days (interquartile range, 15.1–139 d) in allogeneic hematopoietic stem cell transplantation and 14.2 days (interquartile range, 10.5–124 d) in autologous hematopoietic stem cell transplantation. Twenty-eight-day mortality was 46.6%. At 12 months following hematopoietic stem cell transplantation, 89 patients (66.9%) who developed acute respiratory distress syndrome had died. Only 7 of 133 acute respiratory distress syndrome cases met criteria for engraftment syndrome and 15 for diffuse alveolar hemorrhage. Conclusions: Acute respiratory distress syndrome is a frequent complication following hematopoietic stem cell transplantation, dramatically influencing patient-important outcomes. Most cases of acute respiratory distress syndrome following hematopoietic stem cell transplantation do not meet criteria for a more specific post-transplantation pulmonary syndrome. These findings highlight the need to better understand the risk factors underlying acute respiratory distress syndrome in this population, thereby facilitating the development of effective prevention strategies.
Off-Ice Anaerobic Power Does Not Predict On-Ice Repeated Shift Performance in Hockey
Peterson, Ben , Fitzgerald, John S. , Dietz, Calvin C., Ziegler, Kevin S., Baker, Sarah E. , Snyder, Eric M., Peterson, Ben J, Baker, Sarah E

Journal of Strength and Conditioning Research | January 24, 2016 | Volume: 30 | Issue: 9 | Pages: 2375-2381

10.1519/jsc.0000000000001341 | PMID 26808844 Get It

Abstract Peterson, BJ, Fitzgerald, JS, Dietz, CC, Ziegler, KS, Baker, SE, and Snyder, EM. Off-ice anaerobic power does not predict on-ice repeated shift performance in hockey. J Strength Cond Res 30(9): 2375–2381, 2016—Anaerobic power is a significant predictor of acceleration and top speed in team sport athletes. Historically, these findings have been applied to ice hockey although recent research has brought their validity for this sport into question. As ice hockey emphasizes the ability to repeatedly produce power, single bout anaerobic power tests should be examined to determine their ability to predict on-ice performance. We tested whether conventional off-ice anaerobic power tests could predict on-ice acceleration, top speed, and repeated shift performance. Forty-five hockey players, aged 18–24 years, completed anthropometric, off-ice, and on-ice tests. Anthropometric and off-ice testing included height, weight, body composition, vertical jump, and Wingate tests. On-ice testing consisted of acceleration, top speed, and repeated shift fatigue tests. Vertical jump (VJ) ( r = −0.42; r = −0.58), Wingate relative peak power (WRPP) ( r = −0.32; r = −0.43), and relative mean power (WRMP) ( r = −0.34; r = −0.48) were significantly correlated ( p ≤ 0.05) to on-ice acceleration and top speed, respectively. Conversely, none of the off-ice tests correlated with on-ice repeated shift performance, as measured by first gate, second gate, or total course fatigue; VJ ( r = 0.06; r = 0.13; r = 0.09), WRPP ( r = 0.06; r = 0.14; r = 0.10), or WRMP ( r = −0.10; r = −0.01; r = −0.01). Although conventional off-ice anaerobic power tests predict single bout on-ice acceleration and top speed, they neither predict the repeated shift ability of the player, nor are good markers for performance in ice hockey.
Adult-onset respiratory insufficiency, scoliosis, and distal joint hyperlaxity in patients with multiminicore disease due to novel Megf10 mutations
Liewluck, Teerin , Milone, Margherita , Xia, Tian , Engel, Andrew G. , Staff, Nathan P. , Wong, Lee-Jun, Liewluck, T , Staff, Nathan P

Muscle & Nerve | January 23, 2016 | Volume: 53 | Issue: 6 | Pages: 984-988

10.1002/mus.25054 | PMID 26802438 Get It

Establishing an institutional therapeutic apheresis registry
Mann, Steven A. , McCleskey, Brandi , Marques, Marisa B. , Adamski, Jill , Marques, Marisa B

Journal of Clinical Apheresis | January 23, 2016 | Volume: 31 | Issue: 6 | Pages: 516-522

10.1002/jca.21443 | PMID 26801326 Get It

Apheresis was first performed as a therapeutic procedure in the 1950s. The first national therapeutic apheresis (TA) registry was established in Canada in 1981 and other national registries followed, including two attempts at establishing an international TA registry. There is no national registry in the United States. Our large, academic, tertiary hospital has a very active TA service. We created a TA database to track all procedures performed by the apheresis service by transferring data from paper appointment logs and the electronic medical records into a Microsoft Access database. Retrospective data from each TA procedure performed at UAB from January 1, 2003 through December 31, 2012 were entered, including the type of procedure, indication, date, and patient demographics. Microsoft Excel was used for data analysis. During the 10‐year period, our TA service treated 1,060 patients and performed 11,718 procedures. Of these patients, 70% received therapeutic plasma exchange (TPE), 21% received extracorporeal photopheresis (ECP), 4.5% received red cell exchange (RCE), 4.2% received leukocytapheresis, and 0.6% underwent platelet depletion. Among the procedures, 54% were TPEs, 44% were ECPs, 1.3% were RCEs, 0.5% were leukocytaphereses, and 0.1% were platelet depletions. According to the current literature, national and international TA use is underreported. We believe that the UAB TA registry provides useful information about TA practices in our region and can serve as a model for other institutions. Furthermore, data from multiple institutional registries can be used for clinical research to increase the available evidence for the role of TA in various conditions. J. Clin. Apheresis 31:516–522, 2016. © 2015 Wiley Periodicals, Inc.
A new HIF‐1α/RANTES‐driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice
Koh, Mei Yee , Sargis, Timothy, Lemos, Robert, Grandjean, Geoffrey, Charbono, Adriana, Bekiaris, Vasileios , Šedý, John R. , Kiriakova, Galina M., Liu, Xiuping , Roberts, Lewis R. , Powis, Garth , Gagea, Mihai , Ware, Carl F. , Roberts, Lewis R , Koh, Mei Yee

Hepatology | January 23, 2016 | Volume: 63 | Issue: 5 | Pages: 1576-1591

10.1002/hep.28468 | PMID 26799785 Get It

The hypoxia‐inducible factor (HIF), HIF‐1, is a central regulator of the response to low oxygen or inflammatory stress and plays an essential role in survival and function of immune cells. However, the mechanisms regulating nonhypoxic induction of HIF‐1 remain unclear. Here, we assess the impact of germline heterozygosity of a novel, oxygen‐independent ubiquitin ligase for HIF‐1α: hypoxia‐associated factor (HAF; encoded by SART1). SART1−/− mice were embryonic lethal, whereas male SART1+/− mice spontaneously recapitulated key features of nonalcoholic steatohepatitis (NASH)‐driven hepatocellular carcinoma (HCC), including steatosis, fibrosis, and inflammatory cytokine production. Male, but not female, SART1+/− mice showed significant up‐regulation of HIF‐1α in circulating and liver‐infiltrating immune cells, but not in hepatocytes, before development of malignancy. Additionally, Kupffer cells derived from male, but not female, SART1+/− mice produced increased levels of the HIF‐1‐dependent chemokine, regulated on activation, normal T‐cell expressed and secreted (RANTES), compared to wild type. This was associated with increased liver‐neutrophilic infiltration, whereas infiltration of lymphocytes and macrophages were not significantly different. Neutralization of circulating RANTES decreased liver neutrophilic infiltration and attenuated HCC tumor initiation/growth in SART1+/− mice. Conclusion: This work establishes a new tumor‐suppressor role for HAF in immune cell function by preventing inappropriate HIF‐1 activation in male mice and identifies RANTES as a novel therapeutic target for NASH and NASH‐driven HCC. (Hepatology 2016;63:1576‐1591)